kabutan

Daito Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 26%

Mon Apr 14, 2025 3:30 pm JST Earnings

4577 Daito Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

Daito Pharmaceutical Co.,Ltd. <4577> [TSE Prime] announced its financial results after the market closed on April 14th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending May 2025 (June 2024 to February 2025) dropped 34.9% from the same period last year to 2.03 billion yen.

In addition, the full-year consolidated ordinary profit has decreased 25.7%, from the previous forecast of 3.5 billion yen to 2.6 billion yen (compared to 3.92 billion yen in the previous period), leading to an increase in the profit decline rate from 10.8% to 33.7%.

Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit for the December to May period (2H) has decreased 44.3%, from the previous forecast of 2.03 billion yen to 1.13 billion yen (compared to 1.6 billion yen in the same period of the previous year). This changes the outlook from an anticipated profit increase to a projection of a 29.8% decrease in profit.

In the most recent three-month period, from December to February (3Q), the consolidated ordinary profit dropped to 0.56 billion yen, a 30.3% decrease compared to the same period last year. The operating profit margin drastically worsened from 7.7% in the same period last year to 3.3%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jun - Feb, 2022 34,570 4,106 4,077 2,660 84.1 78.9 Apr 13, 2023 J-GAAP
Jun - Feb, 2023 34,662 3,105 3,122 2,339 74.2 79.6 Apr 12, 2024 J-GAAP
Jun - Feb, 2024 36,609 1,869 2,033 1,217 39.9 78.2 Apr 14, 2025 J-GAAP
YoY +5.6% -39.8% -34.9% -48.0% -46.3%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec - May, 2024 Prev 24,416 2,029 2,030 1,392 46.4 17.50 Jan 10, 2025 J-GAAP
Dec - May, 2024 New 24,416 979 1,130 592 19.8 17.50 Apr 14, 2025 J-GAAP
Revision Rate 0.0% -51.7% -44.3% -57.5% -57.5%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2025 Prev 49,000 3,500 3,500 2,300 76.7 35 Jul 12, 2024 J-GAAP
May, 2025 New 49,000 2,450 2,600 1,500 50.0 35 Apr 14, 2025 J-GAAP
Revision Rate 0.0% -30.0% -25.7% -34.8% -34.8%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec - May, 2023 22,785 1,605 1,609 1,743 55.5 15 Jul 12, 2024 J-GAAP
Dec - May, 2024 Guidance 24,416 979 1,130 592 19.8 17.50 Apr 14, 2025 J-GAAP
YoY +7.2% -39.0% -29.8% -66.0% -64.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2023 45,101 5,207 5,169 3,600 113.8 27.27 Jul 14, 2023 J-GAAP
May, 2024 46,895 3,894 3,923 3,295 105.0 30 Jul 12, 2024 J-GAAP
May, 2025 Guidance 49,000 2,450 2,600 1,500 50.0 35 Apr 14, 2025 J-GAAP
YoY +4.5% -37.1% -33.7% -54.5% -52.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Dec - Feb, 2023 10,552 816 808 787 25.0 7.7 Apr 12, 2024 J-GAAP
Mar - May, 2024 12,233 789 801 956 30.5 6.4 Jul 12, 2024 J-GAAP
Jun - Aug, 2024 12,678 849 983 618 20.2 6.7 Oct 11, 2024 J-GAAP
Sep - Nov, 2024 11,906 622 487 290 9.5 5.2 Jan 10, 2025 J-GAAP
Dec - Feb, 2024 12,025 398 563 309 10.1 3.3 Apr 14, 2025 J-GAAP
YoY +14.0% -51.2% -30.3% -60.7% -59.5%

Related Articles